Dr. Lee Schwartzberg: Bone-Targeted Agents Were Last Year's Top Story in Supportive Care

Interview by L Scott Zoeller. 2012 Jan 18, Lee Schwartzberg, MD

To mark 2011, we have asked our distinguished OncologySTAT Advisory Board Members to choose their top story of the year. In this interview, Dr. Lee Schwartzberg discusses his choice for this year in supportive care in oncology. OncologySTAT: In your view, which development in oncology research that occurred in 2011 could have the most significant impact on supportive care oncology?Dr. Schwartzberg: In my opinion, bone-targeting agents, overall, have had the greatest impact in 2011 on supportive care...

NOT A MEMBER?

Registration is FREE

  • Up-to-date oncology news
  • Journal article summaries
  • Commentaries and interviews
  • Drug and interactions database
  • Chemotherapy regimens
  • Daily e-newsletters

 

Meet Our Experts

Meet our Advisory and Editorial Boards comprised of physician editors and world-renowned experts.

Editors' Choice

Everolimus Plus Tamoxifen Improves Survival in Metastatic Breast Cancer

Cancer Type

  • Bladder
  • Bone
  • Breast
  • Breast (ER-Positive)
  • CNS/Brain
  • Colon and Rectum
  • Endocrine System
  • Esophagus
  • GYN (Non-Ovary)
  • GYN (Ovary)
  • Head and Neck
  • Hodgkin's Lymphoma
  • Kidney (Renal Cell)
  • Leukemia
  • Liver and Bile Duct
  • Lung
  • Multiple Myeloma
  • Myelodysplastic Syndrome
  • Myeloproliferative Diseases
  • Non-Hodgkin's Lymphoma
  • Pancreas
  • Pediatric Cancers
  • Prostate
  • Rare Cancers
  • Skin
  • Soft-Tissue Sarcoma
  • Stomach
  • Testicle
  • Forgot your password?
    Not a member? Free registration